Skip to main content
. Author manuscript; available in PMC: 2011 Jan 21.
Published in final edited form as: Invest New Drugs. 2008 Oct 22;27(5):469–475. doi: 10.1007/s10637-008-9190-8

Table 2.

Reasons for Discontinuation of Treatment and Number of Protocol Deviations (N = 25)

Adverse Events or Side Effects 6
Refusal Unrelated to Adverse Events 2
Progression/Relapse 17
Death 0
Other – Not Protocol Specified 0
Major Protocol Deviations 1